

## Corporate Value Enhancement Plan

Report to Board of Directors on Nov. 12, 2025

### [Preface]

In order to promote the importance of shareholders' rights and interests of listed and OTC listed companies and guide them to enhance their corporate value, the Taiwan Stock Exchange revised the "Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies" on August 23, 2024, and announced the amendment and release on August 29, 2024 by the TPEX to facilitate enterprise compliance.

Since its establishment, University Optical Technology Co., Ltd. (hereinafter referred to as "University Optical Technology") has become a leading enterprise in Taiwan's optometry industry with its professional management team and strong technical strength, and has been a long-term partner of many well-known domestic and foreign companies. The company adheres to continuous innovation and forward-looking thinking, and is committed to the realization of smart medical technology and the improvement of its industry status.

In the face of international geopolitical changes, intensified industrial competition, and the wave of digitalization and low-carbon transformation, the company has proposed a plan to enhance corporate value, hoping to further enhance corporate value and ensure the company's long-term sustainable development through current situation analysis and specific strategies.

### [Current Situation Analysis]

#### 1. Cost analysis

##### (1) Weighted Average Cost of Capital (WACC) calculated:

1. The company's capital structure in the first half of 2025 is composed of 98.27% equity and 1.73% debt (99.46% and 0.54% in 2024), indicating that the long-term shareholders' equity is the main source of funds, and the financial structure is quite stable. The company's cost of equity is 6.89%, and the cost of debts is 2.23%, and the factors affecting the cost of debt and equity include corporate credit, operating risk, etc. Through the analysis of the weighted average cost of capital (WACC), the company can evaluate the efficiency of capital use, the appropriateness of the investment plan and the rationality of the enterprise value, and the company's WACC in the first half of 2025 was 6.80% , slightly lower than the industry average. The Company will continue to maintain a stable financial structure and prudent capital utilization strategy to ensure that the cost of funds remains within a reasonable range and serves as an important basis for evaluating the feasibility of investment plans and corporate value.

Due to the risk and innovation of the biotech industry, some biotech companies may have

WACC in the range of 9%-12% (refer to Baoling Fujin 2025.8.12 Enterprise Value Enhancement Plan), and the company belongs to mature biotech companies and usually has a low WACC. We will further analyze these factors to ensure that the cost of funds is within a reasonable range.

year	2025 first half of the year	2024 years
Cost of Equity – UVB	6.89%	7.40%
Cost of Debt – UVB	2.23%	2.50%
<b>WACC – UVB</b>	<b>6.80%</b>	<b>7.37%</b>
WACC – Average of the listed biotechnology and medical industry	7.2%~7.8%	7.4%~8.0%

Source: Provided by the UVB Finance department.

2. Macroeconomic Impact Analysis: Fluctuations in interest rates, inflation rates and exchange rates may have an impact on the Company's WACC, and changes in these factors are relatively controllable to the Company. In addition, the Company will conduct regular overall economic analysis to maintain the relative stability of WACC within a controllable risk range, which will help improve the Company's ability to respond to changes in the dynamic market environment, ensure the rationality of capital costs, and thereby maintain the financial stability of the enterprise.

## 2. Profitability assessment

- (1) **ROIC and ROE evaluation:** The company's operating performance can be measured by return on invested capital (return on investment, return on invested capital) and return on equity (return on equity). ) to evaluate it. Specifically, the Company's return on investment in the first half of 2025 and 2024 was 21.26% and 22.54%, respectively, and the ROIC was significantly higher than that of WACC of 6.80% and 7.37% , indicating that the company's overall capital use efficiency is excellent and the efficiency of capital utilization is fully utilized. In addition, the first half of 2025 and 2024 reached 22.78% and 29.59% respectively, higher than the industry average of 6.87% and 10.98%It is also much higher than the cost of debt (cost of debt) of 2.23% and 2.50%, indicating that the company has effectively used shareholders' equity to obtain good returns and maintained a stable financial structure. The Company's ROIC and ROE performance demonstrate management's effective capital allocation and demonstrate the Company's competitiveness in the biotechnology and medical field.

year	2025 first half of the year	2024 years
<b>ROE – UVB</b>	<b>22.78%</b>	<b>29.59%</b>
ROE – Peer Average	6.87%	10.98%

Sources : Provided by the UVB Finance department.

Note: ROIC = After-tax operating income / invested capital; Invested capital = total assets – interest-free current liabilities (payable, pre-received, etc.).

ROE = Net Profit After Tax / Shareholders' Equity

- (2) **Business analysis:** The company's business items are "e-University" brand licensing and consulting services, providing professional logistical support for cooperative clinics including the introduction and leasing of ophthalmic equipment and maintenance, drug consumables sales, business district evaluation and exhibition store planning and decoration, store leasing and manpower recruitment, personnel administration and other professional logistical support. At the same time, it operates the eye optometry business of directly operated eyewear stores.

In the Taiwan market, there are currently no similar listed vision biotechnology medical service companies in China, and the main competitors of brand authorized cooperative clinics are ophthalmic peers and large hospitals engaged in vision correction. University Glasses is the first professional channel in China to integrate ophthalmic medical care and optometry dispensing, with the concept of "medical optometry and scientific optometry" as the core, caring about the visual health of customers, taking the community and business district as the base channel, combining medicine and one-stop shopping innovative business model, providing local residents with complete professional optical services and high-quality products, and has long won the trust and support of consumers.

Taiwan has entered a "super-aged society" in 2025 years, which means that the proportion of people over 65 years old accounts for more than 20% of the total population. The company will continue to deepen strategic partnerships with leading international suppliers and the introduction of technological medical equipment, and combine community services to launch functional and differentiated products and services, expand market penetration and profitability, and effectively improve operational synergy.

Currently, due to the US tariff 2.0 policy and the continued involution of China's domestic demand market, the company's revenue and profit growth in mainland China are facing headwinds. In order to strengthen competitiveness, the company has actively adjusted the layout of its business bases, and at the same time steadily improved its overall financial performance through cost control and price strategy adjustments.

### 3. Market evaluation analysis

**(1) Evaluation level analysis:** PBR (Price-to-Book Ratio) calculated by the company's closing price at the end of June 2025 (NTD 202 ) 4.72 times, which is higher than the industry average of 2.19 times, indicating that the market has given a positive and reasonable evaluation, reflecting investors' confidence in the company's stable financial structure, sustained profitability and leading business strategy. The PER ( Price-to-Earning Ratio ) is 21.12 times, which is also higher than the industry average of 20.21 times. This is mainly due to the company's long-term low-leverage business strategy, and the market is still waiting and seeing the volatility and geopolitical risks of its business in China. The company will continue to drive service upgrades with technology and medical care, launch high added value with functional new product launches and market competitiveness, consolidate its brand leadership position, and steadily expand its store scale. At the same time, through diversified investor communication mechanisms and transparent information disclosure, the market will strengthen the market's recognition of the company's operational strength and long-term value, and promote the return of evaluation standards to corporate fundamentals.

year	2025.6.30	2024.12.31
Closing price – UVB	NTD 202	NTD 200
<b>Price-to-Book Ratio (PBR) – UVB</b>	<b>4.72 times</b>	<b>4.77 times</b>
Price-to-book ratio (PBR) – The average of the peers	2.19 times	2.22 times
<b>Price-to-earnings ratio (PER) – UVB</b>	<b>21.12 times</b>	<b>15.91 times</b>
Price-to-earnings ratio ( PER ) –The average of the peers	20.21 times	21.21 times

Source: Provided by the University Optical Finance Office;

Note: PBR = Stock price per share / Net value per share; PER = Stock price per share / Earnings per share

**(2) Potential growth assessment:** The company adheres to the vision of allowing the public to "see clearly, comfortably, and see a new future", and will continue to grasp the trends of the medical technology and eye health industries, providing the company with positive market opportunities that can be transformed into operational and evaluation momentum at a steady pace.

In the medical industry, the field of refraction and cataract self-funding is the main source of momentum. The company has completed it one after another in recent years SMILE/SMILE Pro/SMILE Pro 2.0 laser surgical equipment, and gradually expand the market share of surgical volume (from about 50% to 60%). In July 2025, the company introduced a new generation of "EVO ICL (Implantable Collamer® Lens)" to serve people with thin corneas or moderate-to-high myopia, providing patients with a safe, minimally invasive, and reversible new solution.

The short-term strategy will actively promote education, and in the medium term, it is expected to amplify revenue momentum as penetration rate increases. At the same time, cataract self-funded projects remained strong: high-end femtosecond cataract surgery 1H25 accounted for 52.5% of the overall surgical volume (YoY+22%), and high-end intraocular lens 1H25 accounted for 75% (YoY+10.5%), indicating that the demand momentum will continue and will continue to support the growth of the medical side. The company is optimistic about the medium- and long-term growth opportunities brought about by the aging society and the improvement of vision care awareness, and has begun to promote presbyopia and myopia correction and dry eye treatment and care projects to expand the coverage of all-age services.

The optometry business is driven by children's myopia prevention and control and functional lenses, with 1H25 myopia prevention and control products accounting for about 51% of optical revenue (YoY+12%) and functional lenses accounting for 20% (YoY+10%), and brand and channel advantages help continue to grow steadily. In addition, in terms of consumer products and long-term brand power, we continue to focus on the development and launch rhythm of the functional health product "University Jinsan Ming Lutein" to meet the trend of lutein nutritional supplementation for different ages and health needs, and combine store and clinic resources to deepen eye health services throughout the life cycle and strengthen customer stickiness and cross-selling benefits. At the end of 2024, it launched a new "SOS Enhanced" formula design "Jinrun Ming Lutein" to quickly respond to the needs of modern digital life and provide a comprehensive crystal and moisturizing solution.

In terms of channel and base expansion, the goal is to complete 4~5 new cooperation bases in 2025, with locations all over the north, central and southern regions such as Taoyuan Yiwen, Zhubei, Taichung Chongde, and other emerging densely populated or ophthalmic care gap business districts; In 2026~2030, it is planned to continue to have 3~5 stores per year, which is expected to pave the way for subsequent capacity. These strategies are expected to improve capital use effectiveness (ROE), strengthen overall valuation performance, and generate solid and sustainable long-term returns for shareholders.

Finally, according to the research institution's model, according to the growth rhythm, Taiwan's revenue in 2025 and 2026 is expected to be 3.81 billion (YoY+4.8%) and 4.03 billion (YoY+5.7%), respectively, with continuous store expansion, high-end treatments, and the introduction of new services, showing moderate growth. The merger level also estimates that the annual revenue growth rate in 2025 and 2026 will be about +4.54% and +6.04%.

#### **4. Corporate governance analysis:**

##### **(1) Board structure and independence:**

Through the diversity and independence of the Board structure, the Company enables the Board of Directors to fully consider various professional knowledge and perspectives in the decision-making process, and to provide objective opinions and recommendations independently of the Company's management.

##### **1. Structural diversity**

In order to strengthen corporate governance and promote the sound development of the composition and structure of the Board of Directors, Article 20, Paragraph 3 of the Company's "Code of Practice on Corporate Governance" states that the composition of the board of directors should consider diversity and formulate appropriate diversity policies based on its own operations, operating patterns, and development needs, including but not limited to the following two standards:

- Basic conditions and values: gender, age, nationality and culture, etc.
- Professional knowledge and skills: professional background (such as law, accounting, industry, finance, marketing or technology), professional skills and industry experience, etc.

The Company's directors and independent directors have rich practical experience and professional knowledge in the industry, and in addition to their leadership decision-making, crisis management, risk management, and international market views, they also have their own expertise and areas of deep cultivation. Chairman Ou Shufang and Director Lin Pirong are both ophthalmologists; Director Zhou Cande has served the education public service system for a long time and was the executive deputy minister of the Ministry of Education; Director Zhang Hongren is currently the chairman of the biotechnology and medical industry, with a background in public health and medicine; Directors Weng Suhui and independent directors Xiao Minzhi and Liu Wenlong are the core management of the enterprise, specializing in the operation and management, leadership and efficient decision-making of the manufacturing and retail industries, respectively. Yang Yunhua is an independent director of National Chengchi University Law School and has a legal background. Chen Weiru is an associate professor of strategy at China Europe International Business School and serves as an independent director of a number of listed companies in mainland China. The board members as a whole have the necessary abilities to perform their duties.

In terms of gender ratio, 78% of male directors (7 seats) and 22% (2 seats) of female directors are female directors, and we will continue to actively seek female talents with professional abilities and diverse backgrounds in the future, with the goal of gradually

increasing the number of directors of either gender to 1/3.

## **2. independence**

The Company attaches great importance to the independence of the board of directors, and the current board of directors consists of nine directors, of which 4 are independent directors, accounting for 4/9 (i.e. 44%) of the total number of seats, to ensure the soundness of the board structure.

- (1) The number of independent directors of the Company is not less than one-third (i.e. 33%) of the board seats, and the current ratio is 44%; and more than one-half of the independent directors have not served more than three consecutive terms.
- (2) The independent directors all comply with the relevant regulations of the Securities and Futures Bureau of the Financial Supervisory Commission, and have completed the qualification inspection and signed the declaration at the time of election, and there is no situation stipulated in Article 26-3, Paragraphs 3 and 4 of the Securities and Exchange Act between each director and the independent director.
- (3) The procedures of the directors of the Company at each meeting of the Board of Directors of the Company shall comply with the rules of procedure of the Board of Directors of the Company.
- (4) The directors of the Company also serve as employees of the Company and do not exceed one-third of the total number of directors.

## **(2) Effectiveness of the operation of the board of directors:**

In order to implement corporate governance and improve the functions of the board of directors, establish performance goals to strengthen the operational efficiency of the board of directors, in accordance with Article 37 of the Corporate Governance Code of Practice, the board of directors has established a board performance evaluation system, and the board of directors resolved to pass the "Board Performance Evaluation Measures" on March 29, 2017, and the most recent board of directors approved the revision to November 12, 2020. Internal evaluation of the performance of the Board of Directors is conducted annually; External evaluations are conducted at least once every three years by an external professional independent institution or an external team of experts and scholars.

### **External assessment**

The company's most recent external evaluation of the performance of the board of directors was conducted in July 2023 by commissioning an external professional independent organization, the "China Corporate Governance Association", which evaluated the



composition, guidance, authorization, supervision, communication, internal control and risk management, self-discipline and other 8 aspects of the board of directors through questionnaires and on-site visits, and issued a performance evaluation report on the board of directors in September 2023. The evaluation results will be submitted to the board of directors report on November 11, 2023.

#### **Internal self-evaluation**

The scope of self-evaluation includes board members, board of directors and functional committees, which are carried out at least once a year, of which the board of directors performance self-evaluation, the evaluation aspects include participation in the company's operations, decision-making quality, member structure and election, continuing education, internal control, etc., the overall evaluation score is 5 points, and the total average score of the self-evaluation results in 2024 years is 4.99, submitted to the board of directors on March 6, 2025. Overall, the operation of the board of directors, the board of directors and functional committees is perfect, and the company uses the performance evaluation results of the board of directors as a reference when selecting or nominating directors. The results of the performance evaluation of individual directors shall be used as a reference basis for determining their individual directors' remuneration.

### **(3) Information transparency:**

The Company holds regular board meetings and publicly discloses important resolutions of the board of directors immediately after each meeting. Additionally, the information transparency policy includes disclosures and clarifications on material resolution matters to ensure that shareholders fully understand the company's operations and strategic direction.

Adhering to the principles of ethical management and information disclosure, we actively strengthen the timeliness and completeness of information disclosure to protect the rights and interests of investors and enhance the company's transparency. The company discloses financial, business, and corporate governance information on the public information observatory in accordance with regulations, and sets up an "Investor Relations Zone" on the company's official website to continuously update financial statements, annual reports, corporate governance operations, material information, shareholders' meetings, corporate briefings, and other relevant information to ensure that investors can obtain timely and complete reference materials. The company has also established a website in Chinese and English to provide consistent and transparent information to domestic and foreign investors. The collection, updating, and disclosure of relevant information are strictly handled in accordance with the company's internal regulations and operating procedures to ensure the accuracy and timeliness of the content, and comply with laws and



regulations and information disclosure standards.

In addition to holding regular shareholders' meetings and corporate briefings, the Company also proactively explains the Company's operating results, financial status, and governance priorities through multiple channels to assist the market in comprehensively understanding the Company's strategic direction and medium- and long-term development plans. The Company actively responds to investors' concerns, establishes a mechanism for compiling and analyzing investor and market feedback, and uses the collected opinions as an important reference for continuously improving corporate governance and optimizing information disclosure, enhancing the effectiveness of investor relations and corporate trust, and promoting positive interaction between the company and the market.

The Company has communication channels with shareholders/investors:

1. middle(English) website, URL:<https://www.uvb.com.tw/>, in "Investor relations" Relevant financial, business and corporate governance information will be disclosed in the special section.(Permanent installation)
2. Shareholders' meeting (once a year).
3. Legal conference (at least once a quarter).
4. Company appointment (irregular).
5. Annual Report / Sustainability Report (Periodic).
6. Spokesperson and Acting Spokesperson Mailbox (permanent setting).
7. Investor relations mailbox (permanent setting).
8. Information disclosure and reporting of public information observatory (permanent establishment).

#### **(4) Corporate governance and sustainable development:**

While pursuing corporate growth and achieving operational goals, the company also integrates corporate sustainability ESG (Environmental, Social, and Governance) with corporate strategy and operations, gradually promotes various ESG work, and is committed to sustainable corporate operation to improve service quality and create corporate value.

In 2025, in the 11th Corporate Governance Evaluation, it was ranked as the "Top 5% of Companies in the TPEx Listed Company Group" for three consecutive years, and won the highest honor of "Top 10% of Non-Financial Electronic Listed Companies with a Market Value of More than 100 billion yuan" for two consecutive years. In terms of overall sustainability performance, it was included in the Morgan Stanley Capital International MSCI ESG Ranking A for the first time in 2023, and was promoted to AA in 2024. In addition, it was also awarded the "Outstanding Business Person" by the Ministry of Finance

in 2024 and the "TPEX Listed Backbone Partner Award" by the TPEX Exchange in recognition of the company's continuous integrity management and outstanding performance in contributing to the market.

## **5. Risk and Competition Assessment:**

### **(1) Macroeconomic Analysis :**

Global GDP growth is expected to slow to 33.0% in 2025 due to international turmoil and geopolitical tensions, compared to 3.1% in 2026 (Source: IMF) Major economies are affected by global political restructuring, economic and trade turmoil, fluctuations in raw material and energy prices, The uncertainty of monetary policy and the rising impact of trade protectionism are reshaping the global market and supply chain pattern, increasing risks and challenges for future economic development. In 2025, the effects of U.S. tariff policies will sweep the world, bringing profound impacts on international trade, economy, and energy transition, and the global political and economic situation will continue to fluctuate.

In Taiwan, the Comptroller's Office of the Executive Yuan announced that the GDP estimate for 2025 will rise slightly to 4.45% from 4.30% in 2024, but the forecast growth will decrease to about 2.81% in 2026 due to tariffs and external uncertainties. The economic countermeasure signal in the first half of 2025 will change from yellow and red to green (31 points), indicating that the economy has gradually stabilized from a high-heat situation, but has not fallen into a downturn; July is still green and the score remains at 29 points, with momentum slightly converging but overall positive. The annual CPI growth rate for the full year of 2025 is expected to be between 1.76–1.81%, and inflation is below the 2% target line, which is still moderate.

The Company's operating location is mainly in Taiwan, and the overall economy and monetary policy are relatively stable and sound. Inflation and interest rates remain within reasonable limits. However, medical devices and equipment that rely on imports face the dual challenges of exchange rates and climate change, increasing the risk of supply stability and cost control.

With the high global demographic changes (aging and declining birthrate), changes in the consumer behavior of Generation Z, channel diversification, retail consolidation, and rapid layout of international brands, the competition in the optometry industry is becoming increasingly fierce. Taiwan has entered a "super-aged society" in 2025, which is reshaping the market demand for optometry, and consumers' emphasis on health and sustainability,

and the pursuit of better visual quality will be the future development trend, which will have a long-term impact on the company's product strategy, channel layout and brand management.

## **(2) Industry competition analysis:**

For traditional laser medical devices, medical drug consumables, and optical glasses companies, the sales of their products are often resold to hospitals, eye centers, and optical stores through agent distributors, and the sales process is often limited to buying and selling and leasing, and cannot create added value for downstream customers. The company emerges as a medical management consulting and medical technology service business model, relying on the company's own expertise in vision medicine, in the process of delivering or buying and selling goods, to provide customers with more professional technology and advice, and through the synergy of product integrated marketing, it can create added value for customers. Therefore, through professional medical management consulting and integrated optometry products, it will bring more business opportunities to the optometry industry.

The company takes the brand advantage established by the introduction of advanced instruments and technologies as the main competitive niche, so that the brand-authorized cooperative clinics are in a leading position in the vision surgery and eye care industries. The company's number of stores and store efficiency have increased year by year, and in September 2025, there were 31 brand-authorized cooperative clinics in Taiwan and 34 directly operated eyewear stores. Different from the business model of the same industry, which only focuses on product sales, the company combines the medical expertise of cooperative clinics, with the technical backing of "dual-expert gatekeeping" and the original "i Precision Intelligent Fitting Technique", to create an intelligent multifocal real-lens experience field ° This innovative operating model will be a niche market for the development of medical glasses in the future.

As a leading brand of optometry in Taiwan, the company continues to focus on innovation, developing products that are both safe, effective, and convenient to meet the needs of different groups. and grasp market trends, actively promote digital transformation and omni-channel layout, and enhance brand visibility and market share. In addition, we strengthen supply chain resilience and cost control, promote diversified procurement to reduce risks, and integrate sustainable development into the core of our operations to establish long-term competitive advantages and continue to gain market trust and support.

## **[Policies and Programs]**

The company has long adhered to the concept of stable operation and sustainable development, focusing on its core business and continuously pursuing the improvement of operational efficiency and overall competitiveness. Based on the analysis of the current situation, the following plan is formulated to strengthen corporate resilience and create sustainable value through short, medium, and long-term strategies.

### **1. Short-term enhancement plan**

With the "e-University" brand as the core, the company integrates leading ophthalmic care and optometry services in China to provide comprehensive solutions for one-stop physical channels. At the same time, in order to enhance customer experience, we have launched an exclusive e-commerce platform for eyewear products and eye health products to achieve seamless connection between online and offline services, not only serving the majority of online customers but also attracting traffic to physical stores.

- (1) Continue to develop and introduce new medical equipment and application technologies, and introduce cooperative clinics into clinical treatment.
- (2) Actively seek brand-licensed eye clinics willing to cooperate, expand existing marketing channels, and increase market share.
- (3) Virtual and real integration, optometry channels strengthen customer relationship management, provide personalized vision health services for all ages, and implement segmented marketing to create maximum sales opportunities.
- (4) Optimize process design, use digitalization and AI intelligence to improve store operational efficiency and customer experience.
- (5) Establish and strengthen the procurement and distribution system for medical drugs and consumables.

In addition, adhering to the business philosophy of providing high-quality products to the public, combined with biotechnology and food science teams, we have jointly developed the eye nutritional supplement "University Jinsan Ming Lutein" suitable for the whole family. Since its launch, it has won numerous domestic and international awards, such as the "SNQ National Quality Label", "National Biotechnology and Medical Quality Award", "National Brand Yushan Award", "Taiwan Quality Product Gold Award", "National Biotechnology Award", "World Quality Monte Gold Award", and "International iTQi Flavor Excellent Medal".

## **2. Medium- and long-term strengthening plans**

We actively establish long-term strategic cooperative relationships with major optical and biotechnology manufacturers at home and abroad, integrate resource advantages, and jointly promote the innovation and application of optometry products and technologies. Assist the cooperative clinics in introducing relevant technology training and application, and have won unanimous praise from the medical team of the cooperative clinics, optimize the surgical efficiency and services of the cooperative clinics, and bring more advanced medical quality and choices to the cooperative clinics, creating a good reputation for accumulating brands.

### **Ophthalmic Care Market:**

In recent years, the company has continued to introduce high-end ophthalmic technology equipment, including high-end technology equipment and applications such as "femtosecond assisted cataract laser" and "full femtosecond myopia laser" SMILE Pro, and further introduced SMILE Pro 2.0 with AI tracking function in 2024 and a new intraocular lens with low glare and long extended focus, with the advantages of comfort, minimally invasive, reduced dry eyes, fast and safe, assisting partner clinics to provide their customers with comprehensive and high-quality vision correction solutions, and introducing and developing presbyopia myopia laser technology and equipment for partner clinics to meet the increasing market demand of the presbyopia population year by year.

In addition, the market demand for dry eye syndrome is huge, contact lens users and middle-aged and elderly people have many treatment needs, and there is also a need for continuous care of dry eye after laser and cataract surgery.

### **Ophthalmic Optics Market:**

(1) Innovative technology and precision services: e-University brand leads the field of optometry  
The Company has introduced the innovative "University i-Precision Intelligent Fitting System," which integrates 21 clinical optometry procedures with 21 myopia-control diagnostic steps. We are the first optical chain to adopt advanced multi-focus visual-comfort systems from HOYA (Japan) and Essilor (France) across all stores, complemented by the ZEISS iCM centration device, fully automated optometry instruments, AI technology, and big-data analytics. This comprehensive solution provides customers with a holistic, precise, and comfortable eyewear-fitting experience.

We adhere to the core concept of "medical optometry and scientific glasses" and tailor exclusive personalized glasses for each consumer. The product combines professionalism, fashion sense

and technological elements, forming a clear difference from traditional optical stores and affordable and fast glasses dispensing. In the future, we will continue to strengthen myopia prevention and control products and gerontological service packages, lutein eye care products, and personalized product services to comprehensively promote steady growth in revenue and profits.

(2) Big Vision Plan: Comprehensive eye health management

The company's directly operated eyewear stores combine the equipment and technical advantages of partner clinics to actively promote the importance of myopia control and axial length tracking in school children. Through technological innovation and AI applications, we not only introduce advanced fitting equipment but also continuously update diversified myopia control products to enhance the adhesion of students and parents to vision care. With "eye health needs for the whole family and the whole life cycle" as the core, we integrate optometry and myopia prevention and control services into the e-University brand, becoming the first choice for consumers. This not only enhances brand value but also provides comprehensive and reliable eye health solutions for more families.

In order to achieve long-term development goals, we continue to optimize our business structure and increase the output value of single stores in our existing stores. In addition, by combining the channel resources of partner clinics, cross-marketing strategies are implemented to comprehensively strengthen brand benefits. We are committed to leading the market with innovation and professionalism, ultimately achieving our goal of becoming a leading brand in the domestic vision optics industry. Its strategic plan is as follows:

- (1) To become a resource integration platform and chain channel innovative operator in the biotechnology industry, providing more comprehensive vision health-related products and services with a one-time purchase model.
- (2) Continue to cultivate the cross-strait market.
- (3) Deeply cultivating the myopia prevention and control market and the presbyopia glasses market, through technological upgrades, innovative myopia correction solutions, multifocal glasses solutions, expanding the scope of services, consolidating market share, and becoming the preferred optometry brand in the market.
- (4) Establish its own brand and provide products for the biotechnology vision industry. At the same time, in response to market demand, it has become an international supplier of high-end software interfaces for biotechnology and vision, marketing the global medical and optometry markets.
- (5) With a global strategy, we will expand the marketing channels of vision biotechnology and vision optics, and build the largest vision biotechnology and medical channel in Asia.